» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 176-200 of 1083 results.
 
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
controlling the symptoms of patients with COVID-19 Design: This study is a single-center, prospective (...) , fever) confirm COVID-19; Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation; Less than 7 days have passed since the
IRCTID: IRCT20080901001165N55
the symptoms of patients with COVID-19 Design: This study is a single-center, prospective, randomized (...) ) confirm COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of
IRCTID: IRCT20080901001165N53
hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit Design: Clinical (...) /Inclusion and exclusion criteria: Inpatients with COVID-19 in ICU of Shahid Modarres Hospital - Inclusion criteria: Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive PCR
IRCTID: IRCT20200428047228N2
  1. Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19
  2. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  3. Evaluation of the effectiveness of microemulsion containing extracted squalene based on oilseeds for the treatment of COVID-19
  4. Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  5. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19
  6. The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study
  7. Comparing the effectiveness of Lopinavir/Ritonavir/Hydroxychloroquine and Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine treatment regiments in moderate to severe COVID-19 patients
  8. Evaluation of the effect of oral Ivermectin on the outcome of patients with COVID-19 and compare it with the effect of conucntional therapics in patients admitted to Ziaeian, Baharloo, Imam Khomeini in the spring and summer 2020
  9. Effects of pentoxifyliine on clinical outcomes of patients with COVID19: A randomaized double-blind clinical trial
  10. Comparison of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen with Lopinavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19, A randomized, double-blind study
patients with COVID-19 Design: A phase 3, Placebo-controlled, Paralleled, double-blind, randomized (...) population is 84 patients with COVID-19 (42 patients in control group and 42 in study group). Participants (...) ) test for COVID-19 or/and lung involvement in imaging, age ≥18 years, primary clinical symptoms, non
IRCTID: IRCT20200506047323N1
patients with COVID-19 Design: This study is a single-center, prospective, randomized, open-labeled (...) COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of
IRCTID: IRCT20080901001165N56
on clinical and laboratory findings of COVID-19 patients with standard treatment: a randomized (...) of random numbers for 60 admitted patients of confirmed COVID-19 in Masih Daneshvari Hospital from (...) conduct: This study will be performed in Masih Danesvari hospital,Tehran, Iran. 60 covid-19 confirmed
IRCTID: IRCT20200209046427N1
test. Exclusion criteria: previous COVID-19 treatment, allergy and asthma, hypertension, diabetes (...) prescribed medications to treat COVID-19, they will be received 200 cc of medical beer every 4 hours for 5 (...) the Ministry of Health to treat COVID-19. Main outcome variables: The length of hospital stay, fever
IRCTID: IRCT20200428047229N1
symptoms of patients with COVID-19 Design: This study is a single-center, prospective, randomized, open (...) COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of
IRCTID: IRCT20080901001165N50
the symptoms of patients with COVID-19 Design: This study is a single-center, prospective, randomized (...) ) confirm COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of
IRCTID: IRCT20080901001165N51
COVID- 19 Design: Clinical trial with control group with parallel, Open labeled, Randomised Settings (...) Birjand University of Medical Sciences on approved COVID-19 patients. Patients are treated in two groups (...) PCR test for COVID-19 disease or patients who show evidence of lung involvement on CT scans. The
IRCTID: IRCT20200408046992N1
  1. Effect of atorvastatin on mortality rate and symptom improvement in hospitalized patients with COVID-19
  2. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  3. Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19
  4. Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19
  5. Evaluation of the efficacy of the triple combination of interferon beta-1B (IFN β-1b), chloroquine and Kaletra in the treatment and improvement of symptoms in patients with covid -19: Clinical trial.
  6. Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  7. Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms
  8. Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study
  9. Pilot study of the Grapefruit seed extract adjuvant therapy on COVID-19
  10. Comparison of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen with Lopinavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19, A randomized, double-blind study
Study aim: Determining the effect of plasma administration of COVID-19 survivors on one-month mortality of patients with acute respiratory distress syndrome during COVID-19 disease Design: All hospitalized patients with acute COVID-19 respiratory distress syndrome who are eligible are placed in the
IRCTID: IRCT20200409047007N1
pulegium and Urtica) in controlling symptoms in patients with COVID-19 Design: This study is a single (...) cough, shortness of breath, fever) confirm COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than
IRCTID: IRCT20080901001165N49
Study aim: Comparison of the Effectiveness of Tenofovir antiviral drug beside routine drug regime (standard of care) in COVID-19 patients Design: Clinical trial with control group, parallel group trial, open lable, phase 2 on 60 patients. Replacement randomization was used. Settings and conduct: In both
IRCTID: IRCT20200422047168N1
  1. A randomized clinical trial study, comparison of the therapeutic effects of Ivermectin, Kaletra and Chloroquine with Kaletra and Chloroquine in the treatment of patients with coronavirus 2019 (COVID-19)
  2. The effect of probiotics as an adjunctive therapy with mortality outcome, length and rate of hospitalization in Intensive Care Unit in patients with COVID-19
  3. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  4. Evaluation of safety and effectiveness of favipiravir in comparison with Tenofovir Alafenamid in hospitalized patients with COVID-19
  5. Evaluation of adalimumab effect on clinical symptoms including respiratory distress, oxygen saturation and lung involvement of patients with COVID-19
  6. Comparison of therapeutic effects of hemoperfusion in intubated and non-intubated patients with respiratory failure caused by the COVID-19
  7. Evaluation of the efficacy of Favipiravir in comparison with standard medication on clinical and laboratory findings of COVID-19 patients with moderate severity
  8. Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy
  9. An Investigation of the impact of Faramir containing Salvia officinalis leaf extract on the level of serum IL-6 in patients with COVID-19
  10. Evaluation of the efficacy and safety of methylene blue administration for treatment of COVID-19 patients
Coronavirus (COVID-19)-induced pneumonia will be studied. Design: A clinical trial with a control group, with (...) regimen for COVID-19. Control group: patients in the control group will be prescribed the standard regimen for COVID-19. Main outcome variables: The change of pneumonia severity on CT scan images
IRCTID: IRCT20200317046797N1
clinical signs of suspected viral infection, Covid-19 tests will be carried out based on the national (...) group and one placebo group. Main outcome variables: Covid-19 virus infection (...) Study aim: Comparison of the effect of hydroxychloroquine with placebo on prevention of virus Covid
IRCTID: IRCT20120826010664N6
suspected of COVID-19 Determining the Effect of Persian medicine products on Respiratory Rate in Patients With or Suspected of COVID-19 The effect of Persian medicine products on CRP levels of patients with or suspected of COVID-19 The effect of Persian medicine products on lymphocyte levels in patients with or
IRCTID: IRCT20140617018126N2
  1. Study of the metformin effect on the survival and recovery rate of COVID-19 patients
  2. Effect of metformin in COVID-19 mortality rate and symptom improvement
  3. Evaluation of the effect of melatonin on improving the symptoms of patients with COVID-19-double-blind randomized clinical trial
  4. Evaluation of the effectiveness of IVIg therapy on blood (WBC، lymphocyte count), renal (Cr, urea) and liver parameters (AST, ALT) in COVID-19 patients before and after IVIg therapy.
  5. Evaluation of the Effect of Blood Transfusion on the Atrial Blood Oxygen Saturation percentage in COVID-19 patients
  6. A prospective randomized controlled trial comparing the effectiveness of traditional medicine combination based on the Ferula assa-foetida gum - Tragacanth with moderate to severe Coronavirus disease (COVID-19) compared to standard treatment
  7. Assessing the effect of Astaxanthin Phytochemical, Vitamin D3, Omega-3 and Vitamin E سupplement on the severity of COVID-19 Symptoms of Patients with mild to Moderate Severity- a randomized double blind controlled Clinical Trial
  8. Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product on pulmonary & other clinical and laboratory manifestations of patients with or probable of covid-19
  9. Study of Methylprednisolone effects on treatment and clinical symptoms and laboratory signs of Iranian ‎COVID-19 patients: a clinical trial study
  10. Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19
Study aim: 1. comparing Recigen and placebo in the reduction of dyspnea in covid 19 patients 2. comparing Recigen and placebo in the reduction of cough in covid 19 patients 3. comparing Recigen and placebo in the reduction of hypoxia in covid 19 patients 4. comparing Recigen and placebo in the reduction
IRCTID: IRCT20150914024017N1
Study aim: Determining the effect of educational intervention based on social support theory in reducing stress caused by COVID-19 disease epidemic in people with diabetes Design: Samples are 212 people (...) ; suffering from COVID-19 Intervention groups: In this study, there will be two groups of intervention and
IRCTID: IRCT20201213049693N1
Study aim: Determining the effectiveness of "SALIRAVIRA" as a natural product containing of Licorice, Coneflower, Ginseng, Hyssop, Rhubarb and Rosemary extracts to coronavirus load in COVID-19 (...) Participants/Inclusion and exclusion criteria: Inclusion criteria: COVID-19 patient confirmed by positive PCR
IRCTID: IRCT20201220049771N1
pneumonia requiring non-invasive ventilation induced by Covid 19 Design: A clinical trial, with a control (...) conduct: location: Ghaem hospital of Mashhad. All patients will receive standard Covid 19 treatment (...) two groups. Participants/Inclusion and exclusion criteria: Patients with severe covid-19, who
IRCTID: IRCT20220508054780N1
hospitalized covid-19 patients. Design: double blind randomized clinical trail. with control group, phase 3 (...) study. Participants/Inclusion and exclusion criteria: inclusion criteria: consent age 18-75 years covid-19 patients hospitalized patients exclusion criteria: consent not given not within the 18-75 years
IRCTID: IRCT20210515051304N1
old Inclusion criteria: Diagnosis of COVID 19 Patients that do not need to be admitted in hospital (...) Study aim: Evaluating the safety of sofosbuvir 800mg /Daclatasvir 120 mg in outpatient with COVID 19 Design: Study group: one arm open-label study with only one intervention group consists of 50
IRCTID: IRCT20200128046294N3
  1. A Multicentre, Quadruple-blind, Randomized, Parallel-group Study to Compare the Efficacy of Sofosbuvir and Daclatasvir vs. Placebo in the Outpatient Treatment of COVID-19 in adults
  2. The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study
  3. A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment
  4. Evaluation of efficacy and safety of Sovodak (Sofosbuvir+Daclatasvir) in combination with Ribavirin for mild to moderate hospitalized Covid-19 patients compared to standard care regimen (a randomized controlled trial)
  5. Efficacy of Daclatasvir+Sofosbuvir in patients with severe acute respiratory syndrome coronavirus (SARS-COVID-19)
  6. Efficacy of Daclatasvir and Sofosbuvir (Sovodak) with Ribavirin and without Ribavirin in cirrhosis and non cirrhosis patients with HCV in Gastrointestinal and Liver Disease Research Center in 2017
  7. Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patients: a double-blind randomized clinical trial
  8. Evaluating efficacy and safety of sofosbuvir/ ledipasvir in treatment of COVID-19
  9. Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”,and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19
  10. Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir plus Velpatasvir” to “standard of care therapeutic regimen” in patients with COVID-19
to both lungs on moderate to severe cases of COVID-19 pneumonia Settings and conduct: Patients are (...) monitored for 28 days post treatment. Participants/Inclusion and exclusion criteria: Confirmed COVID-19 (...) criteria receive standard national protocol of COVID-19 treatment plus low dose radiotherapy to both lungs
IRCTID: IRCT20200509047366N1
Study aim: To evaluate the safety and efficacy of losartan in COVID-19 Design: One-hundred patients with COVID-19 after taking informed consent including 50 patients in the case group and 50 (...) (COVID-19). Losartan (25mg/BID) in one group and amlodipine (5mg/daily) in another group will be
IRCTID: IRCT20180802040678N4
Study aim: Evaluation of effectiveness‎ of Intravenous vit c in Patients with COVID-19 ‎ Design: Two arm parallel group randomized trial with sample size 110 patients. In case group 55 patients treat (...) probable case of covid-19 At least 18 years old Exclusion Criteria: The Patient with chronic renal diseases
IRCTID: IRCT20200411047025N1
  1. Comparing the effectiveness of Lopinavir/Ritonavir/Hydroxychloroquine and Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine treatment regiments in moderate to severe COVID-19 patients
  2. Evaluating efficacy and safety of hydroxychloroquine + lopinavir or atazanavir/ritonavir combination in patients with COVID-19
  3. Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19: A randomized clinical trial
  4. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19
  5. Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)
  6. Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)
  7. Comparison of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen with Lopinavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19, A randomized, double-blind study
  8. Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19
  9. Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study
  10. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
Loading...